> top > docs > PMC:7200337 > spans > 26796-27064 > annotations

PMC:7200337 / 26796-27064 JSONTXT

Annnotations TAB JSON ListView MergeView

2_test

Id Subject Object Predicate Lexical cue
32505227-26251193-46575293 262-266 26251193 denotes 2015
T84673 262-266 26251193 denotes 2015

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T259 162-170 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T260 165-170 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T280 55-58 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T281 131-132 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T282 162-170 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T116 24-26 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T118 41-43 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T120 156-161 Chemical denotes donor http://purl.obolibrary.org/obo/CHEBI_17891
T121 216-227 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T122 229-231 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T111 122-143 http://purl.obolibrary.org/obo/GO_0071613 denotes granzyme B production
T112 229-234 http://purl.obolibrary.org/obo/GO_0004915 denotes IL-6R

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
858 24-28 Gene denotes IL-6 Gene:3569
859 122-132 Gene denotes granzyme B Gene:3002
860 229-234 Gene denotes IL-6R Gene:3570
879 216-227 Chemical denotes tocilizumab MESH:C502936

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T150 0-268 Sentence denotes In vitro stimulation by IL-6 and soluble IL-6 receptor has previously revealed impaired cytolytic functions (perforin and granzyme B production) by healthy donor NK cells, which can be restored following addition of tocilizumab (IL-6R blockade) (Cifaldi et al., 2015).